 |
There's one benefit of using VIRAMUNE that doesn't come in a pill.
The Vlife on TherapyTM program.
The Vlife on TherapyTM program is a patient education program that provides Viramune® (nevirapine) tablets/oral suspension users with important benefits that go beyond what medicine alone can offer.
A program that provides information, education, and inspiration.
Whether you — or someone you know — has been taking VIRAMUNE in combination with other HIV medicine for years or just started, the Vlife on TherapyTM program is an ongoing source of ideas and perspectives that may help people taking VIRAMUNE:
- Better understand HIV, and help maintain their VIRAMUNE care and treatment plan
- Play a more active role in their health care decisions
- Learn how they may save up to $50 toward their monthly prescription co-pay for up to a year. Go to www.viramune.com for details
- Be inspired by people who lived through similar experiences and want to share them with others
Enroll and receive a medication reminder — while they last.*
Staying on a treatment plan can be a challenge. That's why we are providing new enrollees in the Vlife on TherapyTM program with a medication reminder. It's a special top that fits on the cap of a medicine container that plays a sound when it's time to take medication.
*Supplies are limited.
Click here to enroll now in the Vlife on TherapyTM program.
Sincerely,
The Vlife on TherapyTM Team
Indication and Important Safety Information
VIRAMUNE is indicated for use in combination with other antiretroviral agents for the treatment of HIV infection.
VIRAMUNE does not cure HIV or AIDS, and has not been shown to reduce the risk of passing HIV to others through sexual contact or blood contamination. VIRAMUNE can cause severe liver disease and skin reactions that can cause death. These reactions occur most often during the first 18 weeks of treatment, but can occur later. Ask your healthcare professional (HCP) about how to recognize symptoms of skin and liver problems. Stop taking VIRAMUNE if you have any of these reactions. Do not restart VIRAMUNE if you experience any of these reactions. Call your HCP immediately if you have any of these reactions.
Any patient can experience liver problems with VIRAMUNE, but women and patients who have higher CD4 counts when they begin VIRAMUNE treatment have a greater risk. If you are a woman with CD4+ >250 cells/mm3, or a man with CD4+ >400 cells/mm3, you should not begin taking VIRAMUNE unless you and your HCP have decided that the benefit of doing so outweighs the risk. Women, including pregnant women, with CD4+ cell counts >250 cells/mm3 are at the greatest risk.
Do not take VIRAMUNE if you have severe liver problems.
The dose of VIRAMUNE for adults is one 200-mg tablet daily for the first 14 days, followed by one 200-mg tablet twice daily. VIRAMUNE is always taken with other anti-HIV medications. The 14-day lead-in period is important because it can help reduce your chances of getting a potentially serious skin rash. If you have a skin rash during the first 14 days, immediately contact your HCP and do not increase your VIRAMUNE dose to twice a day. The total duration of the once-daily lead-in dosing period should not exceed 28 days, at which point an alternative regimen may need to be started.
Other side effects that patients have experienced include nausea, fatigue, fever, headache, vomiting, diarrhea, abdominal pain, and myalgia. Changes in body fat may occur in patients receiving antiretroviral therapy. Immune reconstitution syndrome has been reported in patients treated with combination ARV therapy.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please consult full Prescribing Information, including boxed WARNING and
Medication Guide, and Important Safety Information for VIRAMUNE.
|
|
